UNSPSC 51384208: Loxoprofen sodium

This classification denotes a cyclooxygenase inhibitor with the molecular formula C15H17O3.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NDC2M7399S, chemically known as benzeneacetic acid, alpha-methyl-4-((2-oxocyclopentyl)methyl)-, sodium salt, dihydrate but more generally known as loxoprofen sodium, which bears US NIH Compound Identifier 157322. European Medicines Agency schedules Loxoprofen sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02978MIG.

Most nations, for tariff and trade purposes, schedule loxoprofen sodium under HS 29183000 and SITC 51395. As of Q4 2014, LOXOPROFEN SODIUM remains US FDA's Preferred Term for this commodity. SMILES: CC(C1CCC(CC1)CC2CCCC2=O)C(=O)[O-].[NA+].

UNSPSC 51384208 Loxoprofen sodium is a Commodity code. Recent state and local solicitations tagged with this code do not reflect loxoprofen procurement; instead, they show solicitation activity for naloxone, generic multi-source pharmaceuticals, over-the-counter products, and direct-to-manufacturer prescription programs. Naloxone is an opioid antagonist distinct from loxoprofen (a nonsteroidal anti-inflammatory), suggesting a coding mismatch between the UNSPSC classification and the work actually being procured. State and local agencies using this code are primarily health and human services entities and cooperative purchasing alliances. Seminole County, Florida pursued naloxone and drug deactivation systems through competitive bidding; the Texas Health and Human Services Commission issued a Request for Information on direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (administered by the Minnesota Department of Administration) solicited generic pharmaceuticals and OTC products on behalf of participating state and local government facilities across multiple states.

Recent activity concentrates in Florida, Texas, and Minnesota, with multi-state reach through cooperative purchasing vehicles. Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to Sanford, Florida, on a two-year term with one-year renewal option. The Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026) gathered vendor capabilities for direct-to-manufacturer prescription fulfillment without pharmacy benefit manager intermediation. The Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) established contracts for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen, Cardinal Health, and Morris & Dickson), with agreements effective July 1, 2026, and a contract term of two years. The code shows limited recent activity relevant to loxoprofen specifically; the tagged opportunities reflect broader pharmaceutical procurement that does not align with the code's nominal scope.